Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement
- 30 June 2020
- Vol. 75 (7), 1546-1554
- https://doi.org/10.1111/all.14336
Abstract
No abstract availableThis publication has 46 references indexed in Scilit:
- Sublingual allergen immunotherapy in HIV‐positive patientsAllergy, 2015
- A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitisHealth Technology Assessment, 2013
- Mechanisms of Allergen-Specific Immunotherapy and Novel Ways for Vaccine DevelopmentAllergology International, 2013
- Apilimod Inhibits the Production of IL-12 and IL-23 and Reduces Dendritic Cell Infiltration in PsoriasisPLOS ONE, 2012
- SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trialJournal of Allergy and Clinical Immunology, 2012
- One hundred years of allergen immunotherapy: Time to ring the changesJournal of Allergy and Clinical Immunology, 2011
- Allergen-specific immunotherapy with recombinant grass pollen allergensJournal of Allergy and Clinical Immunology, 2005
- IL‐10 and TGF‐β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapyEuropean Journal of Immunology, 2003
- Allergen immunotherapy: Therapeutic vaccines for allergic diseases A WHO position paperJournal of Allergy and Clinical Immunology, 1998
- Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro.JCI Insight, 1996